VREOD — Vireo Growth Inc.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1771706 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
2026-08-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 106,200,000 | 59,300,000 | 17,700,000 | -20,300,000 | 928,800,000 | 122,400,000 | 634,700,000 |
| Dec 2025 | 104,510,462 | 56,882,219 | 2,615,971 | -20,372,228 | 817,154,292 | 102,229,759 | 509,729,300 |
| Sep 2025 | 91,655,155 | 37,382,999 | 1,612,680 | -26,298,861 | 678,918,509 | 97,151,669 | 432,612,987 |
| Jun 2025 | 48,063,010 | 20,417,847 | 2,710,753 | -14,934,029 | 659,340,259 | 99,134,913 | 390,761,769 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$19,011,491
Investing CF
$17,859,451
Financing CF
$14,719,059
CapEx
$-40,016,673
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.00
As of
2026-06-14
Balance + Analyst (yfinance extras)
Retained Earnings
$-319,900,000
Inventory
$76,100,000
Receivables
$35,700,000
ST Investments
$1,000,000
EBIT TTM
$-8,822,270
Pretax Income TTM
$-39,277,118
Interest Exp TTM
$30,454,848
Analysts
1
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 268,769,268 | 10,159,790 | -68,113,908 | 817,154,292 | 509,729,300 | — | 3,711,491 |
| Dec 2024 | 99,384,221 | 18,067,365 | -28,007,509 | 278,862,918 | 223,299,395 | — | -10,234,550 |
| Dec 2023 | 88,133,163 | 10,579,778 | -25,547,089 | 183,263,719 | 199,307,368 | — | -965,906 |
| Dec 2022 | 74,625,867 | -6,939,365 | -42,457,444 | 159,156,403 | 155,715,519 | — | -18,073,265 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $991.62B | $1112.00 | — |
| JNJ | JOHNSON & JOHNSON | $563.77B | $234.20 | — |
| ABBV | AbbVie Inc. | $390.87B | $221.23 | — |
| NVS | NOVARTIS AG | $287.89B | $150.88 | — |
| MRK | Merck & Co., Inc. | $285.12B | $115.44 | — |
News headlines (Yahoo Finance, 1h cache)
Vireo Growth Inc. and C21 Investments Inc. Announce Definitive Arrangement Agreement
2026-06-15 11:00 · Yahoo
D.A. Davidson Acts as Exclusive Advisor to Bridgewell Agribusiness in Sale to Vireo Growth
2026-06-09 23:05 · Yahoo
Vireo Growth Inc. Appoints BDO as its New Auditor
2026-06-09 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.